SEARCH

SEARCH BY CITATION

References

  • 1
    Feldaker M, Hines EA, Jr., Kierland RR. Livedo reticularis with summer ulcerations. AMA Arch Derm 1955; 72: 3142.
  • 2
    Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96: 48999.
  • 3
    Fritsch P, Zelger B. [Livedo vasculitis]. Hautarzt 1995; 46: 21524; quiz 22-3.
  • 4
    Goerge T, Weishaupt C, Metze D, Nowak-Gottl U, Sunderkotter C, Steinhoff M, Schneider SW. Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin. Arch Dermatol 2010; 146: 9278.
  • 5
    Goerge T. Niedermolekulare Heparin-Therapie zur Behandlung der Livedovaskulopathie. Aktuelle Dermatologie 2010; 36: 48487.
  • 6
    Metz J, Sturm G. [Atrophie blanche (so-called capillaritis alba)]. Hautarzt 1974; 25: 1059.
  • 7
    Marzano AV, Vezzoli P, Berti E. Skin involvement in cutaneous and systemic vasculitis. Autoimmun Rev 2012 Aug 16. [Epub ahead of print].
  • 8
    Gonzalez-Santiago TM, Davis MD. Update of management of connective tissue diseases: livedoid vasculopathy. Dermatol Ther 25: 18394.
  • 9
    Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. [comment]. Arch Dermatol 2006; 142: 14812.
  • 10
    Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol 1998; 134: 4913.
  • 11
    Papi M, Didona B, De Pita O, Frezzolini A, Di Giulio S, De Matteis W, Del Principe D, Cavalieri R. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol 1998; 134: 44752.
  • 12
    Emerging Risk Factors C, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 41223.
  • 13
    Hairston BR, Davis MD, Gibson LE, Drage LA. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol. 2003; 139: 98790.
  • 14
    Sunderkotter C, de Groot K. Therapie von Vaskulitiden und Vaskulopathien. Hautarzt 2008; 59: 38293.
  • 15
    Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. Arch Dermatol 2006; 142: 758.
  • 16
    Meiss F, Marsch WC, Fischer M. Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences. Eur J Dermatol 2006; 16: 15962.
  • 17
    Deng A, Gocke CD, Hess J, Heyman M, Paltiel M, Gaspari A. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. Arch Dermatol 2006; 142: 14669.
  • 18
    Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000; 18: 4046.
  • 19
    Kreuter A, Gambichler T, Breuckmann F, Bechara FG, Rotterdam S, Stucker M, Altmeyer P. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. J Am Acad Dermatol 2004; 51: 5749.
  • 20
    Kerk N, Drabik A, Luger T, Schneider SW, Goerge T. Rivaroxaban prevents painful cutaneous infarctions in Livedoid Vasculopathy. Br J Dermatol 2012 Oct 27. [Epub ahead of print].